Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC

SWEET Trial

Switch to Efavirenz + TDF-FTC
SWEET: Study Design

- **Background**: Randomized, controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed on efavirenz-based ART by switching from twice-daily zidovudine-lamivudine to once-daily tenofovir DF-emtricitabine in adults with HIV
- **Inclusion Criteria (n = 234)**
  - Age ≥18 years
  - On EFV + ZDV-3TC for >6 months
  - No resistance to study drugs
  - HIV RNA <400 copies/mL for ≥3 months and HIV RNA <50 copies/mL on 2 occasions
- **Treatment Arms**
  - Efavirenz + TDF-FTC
  - Efavirenz + ZDV-3TC



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 48 Virologic Response (Intention-to-Treat Analysis, Missing=Failure)



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 48: Patients with Change in Absolute Hemoglobin from Baseline



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Limb Fat from Baseline



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Plasma Lipids from Baseline



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Plasma Lipids, by Baseline Cholesterol



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51:562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 48: Change in Plasma Lipids from Baseline



Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51(5):562-8.

Switch to Efavirenz + TDF-FTC
SWEET: Results

Interpretation: “Switching from zidovudine/lamivudine to tenofovir disoproxil fumarate/emtricitabine in persons on efavirenz therapy maintains virological control, establishes a once-daily regimen, results in improvements in hemoglobin and key lipid parameters, and preserves and restores limb fat relative to continuation of zidovudine/lamivudine.”

Source: Fisher M, et al. J Acquir Immune Defic Syndr. 2009;51(5):562-8.

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

AETC AIDS Education & Training Center Program

National HIV Curriculum

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT